Comparative risk of malignancies and infections in patients with rheumatoid arthritis initiating abatacept versus other biologics: a multi-database real-world study

Table 1 Demographics and baseline characteristics of patients in the matched abatacept and other b/tsDMARDs groups

	MarketScan		PharMetrics		Optum
	Abatacept (n = 17,517)	Other b/tsDMARDs* (n = 32,277)	Abatacept (n = 12,120)	Other b/tsDMARDs* (n = 21,145)	Abatacept (n = 3354)	Other b/tsDMARDs* (n = 5604)
Female, %	82	83	80	81	82	82
Age in years at index date, mean (SD)	55 (13)	54 (13)	53 (12)	52 (12)	51 (11)	51 (11)
Co-morbid conditions during the baseline period, %
Malignancy	4.8	4.2	4.5	3.7	3.0	1.9
Cardiovascular disease^†	22	19	21	17	21	17
Hospitalized infections	3.2	2.3	3.5	2.6	3.7	2.9
Other autoimmune diseases^‡	17	15	20	18	17	16
Co-medications^§, %
csDMARDs	56	53	62	58	66	61
b/tsDMARDs	48	15	53	17	59	21
Glucocorticoids	54	53	61	59	71	71

b/tsDMARDs biologic or targeted synthetic disease-modifying antirheumatic drugs, csDMARDs conventional synthetic disease-modifying antirheumatic drugs, SD standard deviation
*Excludes abatacept
^†Includes ischemic heart disease; diseases of pulmonary circulation; other forms of heart disease; cerebrovascular disease; diseases of the arteries, arterioles, and capillaries; diseases of the veins and lymphatics; and other diseases of the circulatory system
^‡Includes psoriatic arthropathy, other psoriasis, diabetes mellitus, multiple sclerosis, systemic lupus erythematosus, vitiligo, toxic diffuse goiter without mention of thryrotoxic crisis or storm, chronic lymphocytic thyroiditis, corticoadrenal insufficiency, acquired hemolytic anemias, immune thrombocytopenic purpura, chronic glomerulonephritis, cirrhosis of liver without mention of alcohol, celiac disease, regional enteritis, ulcerative enterocolitis, postinflammatory pulmonary fibrosis, giant cell arteritis, sicca syndrome, systemic sclerosis, alopecia areata, and urticaria
^§Includes medications taken within 180 days before the index date

ISSN: 1478-6362